Trial site
Azienda Sociosanitaria Territoriale Santi Paolo E Carlo
Milan, 20142, ItalyNot linked to an institution yet
- 8running trials
- 16closed trials
The trials here
What the 24 trials at this site are about, from their registry records.
- Phase
- Phase 317 trials
- Phase 25 trials
- Phase 11 trial
- Phase 2/31 trial
- Status
- Completed16 trials
- Active, not recruiting6 trials
- Recruiting2 trials
- Lead sponsor
- AstraZeneca5 trials
- Anthos Therapeutics, Inc.2 trials
- Bayer2 trials
- Bristol-Myers Squibb Services Unlimited Company2 trials
- Hoffmann-La Roche2 trials
- and 11 more
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
Bioequivalence study on aqueous humour concentrations of active ingredients after topical application of LEVIOSA® versus F2904. Randomized, parallel-group, blinded-assessor study in patients undergoing cataract surgery – BreAK Free
2023-503722-39-00· Phase 1· Ntc S.r.l.· Source
Completed
RANDOMIZED, OPEN LABEL, PARALLEL-GROUP, TWO-ARM, MULTICENTER STUDY WITH CLINICAL ENDPOINT COMPARING PRESERVATIVE FREE BIMATOPROST OPHTHALMIC SOLUTION 0.1 MG/ML AND LUMIGAN® (BIMATOPROST OPHTHALMIC SOLUTION) 0.1 MG/ML IN PATIENTS WITH CHRONIC OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION IN ONE OR BOTH EYES.
2023-504759-28-00· Phase 3· Genetic S.p.A.· Source
Completed
A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes
NCT05901831· Phase 3· Bayer· Source
Completed
PH2a, VH3739937 Proof-Of-Concept in TN HIV-1 Infected Adults
2023-505780-37-00· Phase 2· Viiv Healthcare UK Limited· Source
Completed
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT06132256· Phase 2· Syndax Pharmaceuticals· Source
Active, not recruiting
Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease
NCT05910528· Phase 2· Hoffmann-La Roche· Source
Completed
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
NCT05911360· Phase 3· ViiV Healthcare· Source
Completed
A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2
NCT05737940· Phase 2· AstraZeneca· Source
Completed
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
NCT05742802· Phase 3· AstraZeneca· Source
Terminated
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
NCT05171075· Phase 3· Anthos Therapeutics, Inc.· Source
Completed
A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes
NCT05254002· Phase 2· Bayer· Source
Terminated
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
NCT05171049· Phase 3· Anthos Therapeutics, Inc.· Source
Completed
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
NCT05158387· Phase 3· AstraZeneca· Source
Completed
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
NCT04102098· Phase 3· Hoffmann-La Roche· Source
Completed
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations
NCT04053634· Phase 3· AstraZeneca· Source
Completed
The Late Presenter Treatment Optimisation Study
NCT03696160· Phase 3· NEAT ID Foundation· Source
Report an error